- Clinically significant bleeding within 4 weeks of screening, current use of warfarin, factor Xa inhibitors, and direct thrombin inhibitors unless these medications can be safely discontinued 10 days prior to AMG-232 administration; Note: low molecular weight heparin is permitted; PT/PTT must meet the inclusion criteria; subjects taking warfarin must have their INR followed closely